October 13th 2025
FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes.
FDA approves empagliflozin, empagliflozin plus metformin for pediatric type 2 diabetes
June 21st 2023Children 10 years and older with type 2 diabetes (T2D) can now be treated with empagliflozin and empagliflozin plus metformin hydrochloride to improve blood sugar control, per a recent approval by the FDA.
Diabetes risk perception not associated with greater risk-reducing behaviors
June 13th 2023Intensive lifestyle change remains the primary treatment for youth-onset type 2 diabetes. According to a study in Jama Network Open, there is more work to be done as risk perception and awareness of diabetes alone were not associated with risk-reducing behaviors.
Acute and chronic complications in children with type 1 diabetes mellitus
June 1st 2023Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.
FDA clears algorithm-based automated insulin dosing system for T1D patients 6 years and up
May 25th 2023The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
Equitable access to glucose monitoring improves HbA1c levels
May 8th 2023Hemoglobin A1c improved in youths with newly diagnosed type 1 diabetes (T1D) when inclusive continuous glucose monitoring (CGM) was initiated, irrespective of ethnicity or insurance status. According to a study published in Jama Network Open, universal CGM could play a role in reducing disparities for minoritized racial and ethnic groups.
How insulin changed the way type 1 diabetes was treated in children
April 14th 2023Andrew Lam, MD, retinal surgeon, author, assistant professor, University of Massachusetts Medical School discusses the earliest treatments for type 1 diabetes in children, a topic of his new book, "The Masters of Medicine: Our Greatest Triumphs in the Race to Cure Humanity’s Deadliest Diseases," due out April 18, 2023.